{"Groups": [{"Channels": ["pCDK1/2/3/5", "panCK", "pHH3", "DNA"], "Colors": ["ff0000", "ffffff", "00ff00", "0000ff"], "Name": "Cell Cycle", "Path": "Cell-Cycle_5__CDK1235--10__panCK--30__pH3--4__DNA1"}, {"Channels": ["panCK", "DNA", "CD8a", "CD4"], "Colors": ["ffffff", "0000ff", "ff0000", "00ff00"], "Name": "T cells", "Path": "T-cells_10__panCK--4__DNA1--19__CD8a--17__CD4"}, {"Channels": ["panCK", "DNA", "CD163", "CD68", "CD14"], "Colors": ["ffffff", "0000ff", "00ff00", "ff0000", "ff00ff"], "Name": "Macrophages", "Path": "Macrophages_10__panCK--4__DNA1--21__CD163--22__CD68--23__CD14"}], "Header": "This is a CyCIF image of a biopsy from a patient with triple-negative breast cancer (TNBC) liver metastasis. This biopsy was obtained after the first infusion of Cisplatin (Cis) chemotherapy, before Wee1 inhibitor therapy.", "Images": [{"Description": "No Clinical Benefit - Cisplatin Biopsy", "Height": 15701, "MaxLevel": 4, "Name": "i0", "Path": "https://s3.amazonaws.com/www.cycif.org/keenan-2020/25_C1_a", "Width": 12465}], "Layout": {"Grid": [["i0"]]}, "Rotation": 0, "Stories": [{"Description": "", "Name": "", "Waypoints": [{"Arrows": [], "Description": "We observed high expression of phosphorylated CDK1/2/3/5 and low expression of pHistone H3 in pan-cytokeratin+ tumor cells after the first dose of Cisplatin.", "Group": "Cell Cycle", "Name": "Cell Cycle", "Overlays": [{"height": 0.030965724496426317, "width": 0.029950454840805718, "x": 0.06954556344126976, "y": 0.70274310175198}], "Pan": [0.06729293389286169, 0.7198757771905764], "Zoom": 9.093687247547603}, {"Arrows": [], "Description": "Before Wee1 inhibition, only a few CD4+ and CD8a+ tumor infiltrating lymphocytes (TILs) were present.", "Group": "T cells", "Name": "T cells", "Overlays": [{"height": 0.024653226846315768, "width": 0.02024025680842105, "x": 0.05984037562261067, "y": 0.7084257960251539}], "Pan": [0.05400592004366331, 0.716657682441996], "Zoom": 13.598900551232713}, {"Arrows": [], "Description": "In this biopsy, we observed a moderate number of CD14+ myeloid cells, in addition to CD68+ and CD163+ macrophages, prior to Wee1 inhibitor therapy.", "Group": "Macrophages", "Name": "Macrophages", "Overlays": [{"height": 0.028666436112254612, "width": 0.02734661861169043, "x": 0.058177578081330804, "y": 0.7046375088001847}], "Pan": [0.052848181060204516, 0.720619849272768], "Zoom": 9.807145026844909}]}]}